Bill Sardi's Knowledge of Health: Wrong twist to folic acid study; new statin drug promotion

November 5, 2008

Knowledge of Health Inc,.

457 West Allen #117 San Dimas, CA 91773 USA

www.KnowledgeofHealth.com

Email: admin

November 4, 2008

Researchers Twist Folic Acid Study To Falsely Indicate Failure.

Up Next, A New Study Will Hide The Fact That Statin Drugs Don't Reduce Coronary

Heart Disease Mortality Rates And Will Promote A Statin

Drug (Crestor/Astra-Zeneca) For Its Ability To Reduce Arterial Inflammation

By Bill Sardi

A growing question has been whether supplemental folic acid causes or prevents

cancer?

Scientific arguments have been lodged, to and fro, in favor or opposing folic

acid supplementation and food fortification (see abstracts below). Folic acid

is needed to repair DNA and therefore ought to prevent gene mutations and

cancer. However, in the same vein, folic acid may enhance DNA repair in cancer

cells and cause them to survive rather than being killed off by the immune

system or by cancer treatment. So studies were called for.

So now a definitive study is produced among 5442 female doctors, average age 63,

and mega-dose (2500 micrograms, or 2.5 milligrams) supplemental folic acid did

not increase the risk for cancer.

But notice how this was reported. The news headline read " B Vitamin Supplements

Do Not Prevent Cancer. " Instead of saying " Folic Acid Supplementation Study

Allays Fears Folic Acid Promotes Cancer, " researchers and doctors chose to put a

negative spin on the story.

Two other studies said the same thing in July, but the news media largely chose

to ignore them (see abstracts below).

This provides more evidence that the research community is working hand-in-hand

with the pharma-doctor cartel to mischaracterize critical nutrients need for

repair of the human body.

Upcoming

The next falsehood is that Crestor is the most potent statin for lowering both

cholesterol and C-Reactive Protein (CRP), a marker of inflammation, which will

be said to reduce heart disease risk (but will it save lives?). This would

widen the use of Crestor to all middle-aged adults even with low cholesterol

levels.

As Forbes Magazine says, " The original purpose of statin drugs was to keep

gunky cholesterol from building up. But some scientists argue they also lower

artery inflammation, which can cause cholesterol plaque to burst into

heart-attack-causing clots. A study to be published on November 9, called the

Jupiter study, " tested the theory that Crestor combats this swelling in 18,000

people whose blood tests showed low levels of bad cholesterol (average: 104

milligrams per deciliter) but high levels of C-reactive protein (CRP), which

could indicate that the arteries are inflamed. "

In March the study was stopped early because of " unequivocal " benefit (remember

the Vioxx study that was based upon premature data and then Vioxx turned out to

cause the early demise of thousands of Americans?). Now some scientists " are

hoping for blowout results when the full data are presented on Nov. 9, " says a

report in Forbes Magazine.

Notice that the last abstract provided below, as listed by the National Library

of Medicine, by Drs. John Abramson and James Wright, which reveals statin drugs

do not reduce cardiac mortality rates, no longer provides a synopsis of their

study, but now says " no abstract available. " The National Library of Medicine

and The Lancet have chosen to hide the fact statin drugs don't work.

Meanwhile, a review of the medical literature reveals fish oil, vitamin C,

vitamin E, and red wine molecules all lower inflammation as measured by CRP.

Check references below.

websites.

References for the above statements are provided below:

________________________________

Vitamin B supplements do not prevent cancer: study

Tue Nov 4, 2008 5:04pm EST

By Will Dunham

WASHINGTON (Reuters) - Vitamin B supplements do not appear to protect against

cancer as some previous research had suggested, according to a U.S. study

published on Tuesday.

Women who took a daily supplement that included vitamins B6 and B12 and folic

acid, also known as vitamin B9, for about 7-1/2 years were no more or less

likely to develop or die from cancer than women who took a placebo, the

researchers said.

" This study shows that supplementation with the combined B vitamins provided no

beneficial effect and no harmful effect. So in terms of cancer risk, this may

not be an effective approach, " Dr. Shumin Zhang of Brigham and Women's Hospital

and Harvard Medical School in Boston, who led the study, said in a telephone

interview.

Researchers have been exploring whether a number of different vitamins may

protect against cancer.

The study, published in the Journal of the American Medical Association,

involved 5,442 female health-care professionals from around the United States.

Their average age was 63.

The women had cardiovascular disease or risk factors for it such as high blood

pressure or high cholesterol levels.

Some experts had been hopeful that B vitamins might protect against cancer after

earlier studies indicated that people who get more of these vitamins may have a

lower risk of developing cancer, especially colon cancer.

But in the new study, the number of women who developed cancer was nearly

identical in the vitamin supplement group (187 women) and the placebo group (192

women). The two groups had similar risks for developing any type of cancer or

dying from any type of cancer.

The study did find that among women 65 and older, those getting the daily B

vitamins were 25 percent less likely to develop any type of cancer and 38

percent less likely to get breast cancer. But Zhang said it is not clear whether

this is a genuine finding or simply a chance result.

Cancer Epidemiol Biomarkers Prev 2008 Jun;17(6):1360-7.

Does folic acid supplementation prevent or promote colorectal cancer? Results

from model-based predictions.

Fred Hutchinson Cancer Research Center, Biostatistics and Biomathematics, 1100

Fairview Avenue North, M2-B500, Seattle, WA 98109-1024, USA. gluebeck

Folate is essential for nucleotide synthesis, DNA replication, and methyl group

supply. Low-folate status has been associated with increased risks of several

cancer types, suggesting a chemopreventive role of folate. However, recent

findings on giving folic acid to patients with a history of colorectal polyps

raise concerns about the efficacy and safety of folate supplementation and the

long-term health effects of folate fortification. Results suggest that

undetected precursor lesions may progress under folic acid supplementation,

consistent with the role of folate role in nucleotide synthesis and cell

proliferation. To better understand the possible trade-offs between the

protective effects due to decreased mutation rates and possibly concomitant

detrimental effects due to increased cell proliferation of folic acid, we used a

biologically based mathematical model of colorectal carcinogenesis. We predict

changes in cancer risk based on timing of

treatment start and the potential effect of folic acid on cell proliferation

and mutation rates. Changes in colorectal cancer risk in response to folic acid

supplementation are likely a complex function of treatment start, duration, and

effect on cell proliferation and mutations rates. Predicted colorectal cancer

incidence rates under supplementation are mostly higher than rates without folic

acid supplementation unless supplementation is initiated early in life (before

age 20 years). To the extent to which this model predicts reality, it indicates

that the effect on cancer risk when starting folic acid supplementation late in

life is small, yet mostly detrimental. Experimental studies are needed to

provide direct evidence for this dual role of folate in colorectal cancer and to

validate and improve the model predictions.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1360-7..